New data show Rybrevant plus Lazcluze extends overall survival in patients with EGFR-mutated non-small cell lung cancer, with the median survival benefit expected to exceed one year compared to osimertinib.
New data show Rybrevant plus Lazcluze extends overall survival in patients with EGFR-mutated non-small cell lung cancer, with the median survival benefit expected to exceed one year compared to osimertinib.
Read More
The combination regimen was approved for the first-line treatment of adults with locally advanced or metastatic non-small cell lung cancer with specific EGFR mutations.
Read More
The unexpected finding of pre-existing T-cell reactivity to the AstraZeneca and Janssen vaccines may explain why some people rarely developed thrombotic thrombocytopenia syndrome after vaccination.
Read More
Janssen had been enrolling participants in a phase 3 trial to demonstrate the efficacy of its RSV vaccine candidate in adults age 60 and older.
Read More
The outcomes for patients with pulmonary arterial hypertension taking macitentan and tadalafil together in a single pill have been detailed in a new study, which shows significant improvement compared to those taking either drug alone.
Read More
The FDA limited authorized use of the J&J Janssen COVID-19 vaccine to certain individuals due to risk of thrombosis with thrombocytopenia syndrome.
Read More
The Johnson & Johnson booster reduced the risk of hospitalization from COVID-19 among healthcare workers in South Africa after Omicron became the dominant variant
Read More
Vaccines conferred protection from all COVID-19 variants but there was reduced antibody neutralization of both the Beta and Delta variants.
Read More
The FDA authorized single booster doses for the Moderna Inc and Janssen COVID-19 vaccines for certain adults age 18 and older, as well as the use of “mix and match” boosters of differing vaccines.
Read More
The FDA has approved Janssen Pharma’s Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Read MoreBiolyse Pharma Corp., which makes injectable cancer drugs, was gearing up to start making generic biologic drugs, made from living organisms. Then the pandemic hit.
Read More
Following a safety review, the FDA and the CDC have lifted the recommended pause on the Johnson & Johnson COVID-19 vaccine.
Read More
US regulators are recommending a halt in administration of the Janssen COVID-19 vaccine from Johnson & Johnson after several unexplained cases of blood clots in women who received the shot.
Read More
Maureen Ferran, a virologist at the Rochester Institute of Technology, explains how this third authorized vaccine works and explores the differences between it and the Moderna and Pfizer–BioNTech vaccines that are already in use.
Read More
A US FDA analysis of data submitted by Johnson & Johnson determined that the one-shot Jansen COVID-19 Vaccine was effective at preventing severe disease and is safe to administer.
Read More
Once approved, Johnson & Johnson expects to supply 100 million doses of its COVID-19 vaccine to the US in the first half of 2021.
Read More
The vaccine candidate had an 85% overall efficacy at preventing severe disease 28 days after vaccination and a 66% overall efficacy rate in preventing moderate-to-severe COVID-19.
Read More
The COVID-19 vaccine candidate from Johnson & Johnson is suffering production delays that may affect its distribution by as much as two months.
Read More
STAT News reported that Johnson & Johnson’s Covid-19 vaccine study has been paused due to an unexplained illness in a study participant.
Read More
Johnson & Johnson is aiming to initiate a Phase 1 clinical study of its COVID-19 vaccine candidate in September 2020 and hopes to have it available for emergency use in early 2021.
Read More
Johnson & Johnson is scrapping its investigational therapy for respiratory syncytial virus (RSV) and human metapneumovirus to the tune of a $900 million tax write-off.
Read MoreTreatment with pimodivir significantly decreased viral load over seven days versus placebo, in adult patients with acute, uncomplicated seasonal influenza A.
Read More
The US FDA granted approval for a stronger concentration of one pulmonary arterial hypertension medication and expands the approval of another.
Read More
